Trial · NCT02802501
Adverse events126
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 126
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory tract infection | Infections and infestations | DHA-PQP Only | 7 | 50 | 7 |
| other | Upper respiratory tract infection | Infections and infestations | Tafenoquine+ DHA-PQP | 11 | 50 | 13 |
| other | Upper respiratory tract infection | Infections and infestations | Primaquine+DHA-PQP | 8 | 50 | 8 |
| other | Upper respiratory tract infection | Infections and infestations | DHA-PQP Only (Open-label Primaquine Phase) | 0 | 6 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Tafenoquine 300 mg+DHA-PQP (Open-label Primaquine Phase) | 0 | 12 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Primaquine 15 mg+DHA-PQP (Open-label Primaquine Phase) | 0 | 26 | 0 |
| other | Nasopharyngitis | Infections and infestations | DHA-PQP Only | 7 | 50 | 8 |
| other | Nasopharyngitis | Infections and infestations | Tafenoquine+ DHA-PQP | 5 | 50 | 6 |
| other | Nasopharyngitis | Infections and infestations | Primaquine+DHA-PQP | 2 | 50 | 2 |
| other | Nasopharyngitis | Infections and infestations | DHA-PQP Only (Open-label Primaquine Phase) | 0 | 6 | 0 |
| other | Nasopharyngitis | Infections and infestations | Tafenoquine 300 mg+DHA-PQP (Open-label Primaquine Phase) | 0 | 12 | 0 |
| other | Nasopharyngitis | Infections and infestations | Primaquine 15 mg+DHA-PQP (Open-label Primaquine Phase) | 0 | 26 | 0 |
| other | Rhinitis | Infections and infestations | DHA-PQP Only | 3 | 50 | 3 |
| other | Rhinitis | Infections and infestations | Tafenoquine+ DHA-PQP | 4 | 50 | 4 |
| other | Rhinitis | Infections and infestations | Primaquine+DHA-PQP | 2 | 50 | 2 |
| other | Rhinitis | Infections and infestations | DHA-PQP Only (Open-label Primaquine Phase) | 0 | 6 | 0 |
| other | Rhinitis | Infections and infestations | Tafenoquine 300 mg+DHA-PQP (Open-label Primaquine Phase) | 0 | 12 | 0 |
| other | Rhinitis | Infections and infestations | Primaquine 15 mg+DHA-PQP (Open-label Primaquine Phase) | 0 | 26 | 0 |
| other | Pharyngitis | Infections and infestations | DHA-PQP Only | 0 | 50 | 0 |
| other | Pharyngitis | Infections and infestations | Tafenoquine+ DHA-PQP | 5 | 50 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02802501/events